A recent study with mirabegron 50 mg and 25 mg in Chinese participants with overactive bladder (OAB) has been completed. The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of OAB in Chinese participants. Additionally, the study evaluated the safety of mirabegron for the treatment of OAB, assessed other efficacy variables, and explored different mirabegron starting doses. The study was sponsored by Astellas Pharma China, Inc. and involved 249 participants in China.
---
Source: ClinicalTrials.gov
Nghiên cứu & Báo cáo23 thg 8, 2026•1 phút đọc
Mirabegron Study for OAB Completed
3
1
Astellas Pharma's mirabegron study for overactive bladder in China is completed. The study evaluated efficacy and safety of mirabegron.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: ClinicalTrials.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá